Comparing the Therapeutic Efficacy and Safety of DA-9701 With Domperidone in Patients With Parkinson's Disease Evaluated by Real-time Ultrasonography: A Randomized Double-blinded Clinical Trial

Trial Profile

Comparing the Therapeutic Efficacy and Safety of DA-9701 With Domperidone in Patients With Parkinson's Disease Evaluated by Real-time Ultrasonography: A Randomized Double-blinded Clinical Trial

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Jun 2018

At a glance

  • Drugs DA 9701 (Primary) ; Domperidone
  • Indications Constipation; Dyspepsia
  • Focus Therapeutic Use
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 05 Jun 2018 Primary endpoint (Change of gastric motility evaluated using MRI from baseline at 4 weeks after the treatment) has been met, according to results presented at the Digestive Disease Week 2018.
    • 05 Jun 2018 Results presented at the Digestive Disease Week 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top